Consensus $308.22M. Raises FY26 adjusted EBITDA view to $115M-$135M from $100M-$125M. The company said, “CorMedix (CRMD) updates previously established guidance for 2026 net revenue and adjusted EBITDA. The Company increases full-year 2026 net revenue guidance to a range of $325 to $345 million, and full-year adjusted EBITDA guidance to a range of $115 to $135 million.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CRMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- 3 Best Cheap Stocks Under $10 Worth Watching in May 2026
- Citizens healthcare analysts hold an analyst/industry conference call
- CorMedix price target raised to $14 from $13 at RBC Capital
- Buy Rating Reiterated on REZZAYO Trial Strength and Safety Profile; $13 Price Target Maintained